
    
      A multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging
      study of SB-480848, an oral lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, in
      subjects with stable coronary heart disease (CHD) or CHD-risk equivalent to examine chronic
      inhibition of Lp-PLA2, effects on circulating biomarkers associated with cardiovascular risk,
      safety and tolerability over 12 weeks
    
  